FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts

The FDA, on Thursday, announced there is no evidence that diabetes and obesity drugs belonging to the popular glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class of medicines cause suicidal thoughts or actions.The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. GLP-1 drugs are approved f ...